Key facts
- TILT Biotherapeutics’s last known valuation is $100.2M (Jun 2024).
- It has raised $82.0M; the latest was Later Stage VC ($25.6M) in May 2025.
- Notable investors include European Innovation Council, European Commission, Business Finland, Lifeline Ventures, Tesi — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for TILT Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for TILT Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TILT Biotherapeutics
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses to enhance tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors to achieve similar results.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2013
- Employees
- 27
- Website
- tiltbio.com/
- Ownership
- Privately Held (backing)
TILT Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TILT Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TILT Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.